All Clinical Trials

Clinical Trial NCT05144256

AG348-C-022, A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly Transfused, Followed by a 5-Year Open-label Extension Period

  • ClinicalTrials.gov ID: NCT05144256
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: KATHRYN ELYSE DICKERSON

summary

nada!

objective

To determine the efficacy of treatment with mitapivat compared with placebo, as assessed by the reduction in transfusion burden in pediatric subjects with PK deficiency who are regularly transfused

If you are interested in this clinical trial, please contact Laurie Rodgers-Augsutyniak on the Children’s Health Research Team.Call 214-456-6095Email